Daniel Lin-Arlow noticed that DNA writing had barely changed in a decade, so he helped build a company to fix it. ansabio.bio/4BkURZh

Great conversations at ELRIG Drug Discovery this week where we presented a poster in collaboration with Axio Biopharma. Missed us at the meeting? Download the poster: ansabio.bio/4yyMKG4

More DNA. Less bench work. Announcing DNA SCALE-UP, a new product add-on for Clonal DNA and XL Clonal DNA orders. Get consistent, high-purity DNA from the same verified clone, w/o re-culturing & re-prepping. 🧪hubs.li/Q04z9DX60

Avoid dead-end workflows when your fragment request hits a limit. With IDT and @AnsaBio, there’s a better path forward. ⏩ Our “No Loose Ends” workflow helps guide complex designs beyond fragment fit—toward fully assembled clonal genes, without losing momentum. 🧬 So when your project gets more ambitious, your workflow doesn’t stall. Learn more here: idtb.io/07t7jr

𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗔𝗦𝗛𝗚 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗠𝗼𝗻𝘁𝗿𝗲𝗮𝗹? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁! 🧬 Schedule time to meet with the Ansa team and explore how our enzymatic DNA synthesis platform can help advance your research. 👉Schedule time to meet: ansabio.bio/4jjb9eN

Two biosecurity wins! CA enacted gene synthesis screening requirements, and Ansa joined the International Gene Synthesis Consortium. ➡️ AB 1864: lnkd.in/ey7yA5Fs ➡️ IGSC: lnkd.in/g6ZxJJeh

Every company has an origin story. Ours starts with a paper, a polymerase, and a lot of frustration with the DNA our founders couldn't buy. 🧬 Let's revisit where it all began: hubs.li/Q04yLJFD0

400 institutions served. Up to 50kb. 97% fulfillment. 42x increase in complexity. IDT+@AnsaBio is a partnership that pushes beyond the traditional 7kb synthesis ceiling, and resets standards. Get greater design freedom here: idtb.io/07t7jr

Case Study: hubs.li/Q04ydXv_0 The best-expressing antibody DNA is often what vendors call "complex." With @AxioBiopharma, we tested 21 AI codon-optimized mAbs: Vendor X: 11 rejected, 10 flagged complex Ansa: 21/21 standard In CHO: higher titers for 19/21, avg 1.9x

At Ansa, pushing the boundaries of DNA synthesis goes hand in hand with responsible innovation. Our SVP of Informatics, Scott Fay, spoke to @GenomeWeb about the industry’s responsibility to advance #AI & #DNAsynthesis technologies safely. hubs.li/Q04y8q8w0 #biosecurity

"Hard to synthesize" is almost never a synthesis problem. Repeats, GC extremes, and homopolymers each fail at particular steps of a DNA manufacturing workflow — and not at the others. Learn what makes DNA sequences hard to synthesize in our new article: hubs.li/Q04xGdpb0

📣 We’re proud to partner with Waterfall Scientific on ESCALATOR, an ARPA-H GIVE project advancing on-demand production of high-purity mRNA therapeutics and vaccines. Read more: hubs.li/Q04wp1N70

We’re expanding our partnership with @idtdna to make ambitious designs easier to turn into research-ready DNA. Now: feasibility, pricing & turnaround before checkout for constructs up to 50 kb. 400+ institutions. 33 countries. 97% fulfillment. 👉 hubs.ly/Q04w3pG30

In June, 96% of Ansa orders shipped on time or early. 𝗧𝗵𝗲 𝗼𝘁𝗵𝗲𝗿 𝟰% 𝗦𝗵𝗶𝗽𝗽𝗲𝗱 𝗳𝗿𝗲𝗲. That's the Ansa On-Time Guarantee: miss the date, you don't pay. 𝟵𝟵.𝟴% 𝗼𝗳 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗲𝘀 𝘄𝗲𝗿𝗲 𝗳𝘂𝗹𝗳𝗶𝗹𝗹𝗲𝗱. See how it works: hubs.li/Q04tJT5z0

💡 Fun Fact Friday: We went from 600 bp → 50 kb in just 15 months. The bigger story? Expanding what researchers can design, build, and explore. More design freedom. More possibilities. More room to push science forward. What will you build with 50 kb? hubs.li/Q04t4hp20

Today’s AI models can predict expression, optimize sequences, design CRISPR guides, and generate entirely new proteins and DNA sequences. The challenge is turning those digital designs into physical constructs that can actually be tested. Let's dive in! hubs.li/Q04sPdvK0

🧬 AI can now design mRNA sequences no one would've thought to try. The catch? Some of them are nearly impossible to actually build. Our CSO & Co-founder, @dan161803 spoke with @biocompare about this gap between AI-designed and AI-buildable. 👉 hubs.li/Q04r_45V0

Synthetic DNA companies don't usually ask to be regulated. We're doing it anyway. In a new op-ed for @TheScientistLLC , our CEO @Jason_Gammack argues that the current biosecurity screening honor system isn't enough. Read the full piece here: hubs.li/Q04r1-9G0

🧬 𝗬𝗼𝘂 𝗮𝘀𝗸𝗲𝗱, 𝘄𝗲 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱! By popular request, we're extending our iGEM Competition program submission window for 𝘁𝘄𝗼 𝗺𝗼𝗿𝗲 𝘄𝗲𝗲𝗸𝘀 — now closing 𝗝𝘂𝗹𝘆 𝟯𝟭𝘀𝘁. Don't miss this extended window — submit today! 👉 ansabio.com/igem

🔎 DNA synthesis biosecurity runs largely on the honor system today. As generative AI lowers the barrier to designing harmful biological agents, that's no longer good enough. Ansa's VP of Informatics, Scott Fay, shares his perspective on what's needed. hubs.li/Q04pvwxM0